In this work we quantified the in vitro calibration relationships between high frequency electrical stimulation and GABA and glutamate release in both mature retinoic acid differentiated P19 neurons and immortalized embryonic cortical cells engineered to express glutamic acid decarboxylase, GAD65. Extracellular glutamate and GABA was quantified by 2D gas chromatography and time of flight mass spectrometry after stimulation at varying amplitudes and frequencies. Amplitude sweeps resulted in a linear calibration for P19 neurons; the level of neurotransmitter varied over one order of magnitude from ∼ 200 pg/neuron to ∼ 1.2 ng/neuron for glutamate and ∼ 1 ng/neuron to ∼ 2 ng/neuron for GABA, depending on the stimulation amplitude. Frequency sweeps resulted in a peak release at 250 Hz for glutamate and 400 Hz for GABA in P19 cells. The GABA transporter inhibitor, nipecotic acid, increased extracellular GABA levels and decrease glutamate. In contrast the embryonic cortical cells had a strongly nonlinear dependency of release on stimulation amplitude, and a weak dependence on frequency. These cells had roughly equal extracellular glutamate and GABA levels after stimulation despite the expression of GAD65. In addition glutamate and GABA levels were insensitive to nipecotic acid. These results demonstrate an ability to calibrate and tune neurotransmitter release from neural cells using high frequency stimulation parameters.
Introduction
Direct electrical stimulation of the brain by implanted electrodes, e.g. deep brain stimulation (DBS) and responsive neural stimulation (RNS), is an alternative therapy for neurological disorders including Parkinson's disease (Limousin et al. 24, 25 ) and epilepsy (Boon et al. 4 ; Lim et al. 2 ; Wyckhuys et al. 46 ). The therapeutic efficacy of high frequency stimulation (> 100 Hz), HFS, to treat Parkinson's disease is now an accepted human therapy. The effect on motor function in Parkinson's patients is highly dependent upon frequency with optimal frequencies ranging from 130-180 Hz (Moro et al. 34 ). Stimulation parameters are optimized experimentally, and the mechanism of HFS action remains uncertain (Liu et al. 27 ). Basic questions such as whether HFS results in activation or inhibition of the neural target remain unanswered. Recent thinking indicates that HFS more likely results in simultaneous effects on both inhibition and excitation that depend upon the cellular and network properties (Montgomery and Gale 33 ).
As stimulation therapies expand from Parkinson's to epilepsy, stimulation paradigms that can terminate or prevent seizure have been more difficult to identify and trial and error approaches appear insufficient. As this technique matures, questions regarding optimal stimulation parameters must be answered. The therapeutic strategy typically is to modulate (activate or inhibit) an anatomical region in order to counter, eliminate, or replace pathological activity. The rational selection and optimization of stimulation parameters, therefore, requires fundamental knowledge of input-output functions that relate stimulation characteristics and neural activity and to the release of inhibitory and excitatory neurotransmitters within populations of cells.
In addition to direct electrical stimulation therapies, our laboratories are developing hybrid cellular silicon implants to deliver temporally and spatially controlled neurotransmitter by stimulation of cells that are co-implanted with the electrodes. The method combines cell transplantation with electrical prosthesis to enable selective inhibition or excitation using exogenous cells as a chronic neurotransmitter source and stimulation target. In the case of epilepsy we know that local chemical modulation of GABAergic inhibition (Iadarola and Gale 17 ;
McNamara et al. 31 ; Loscher et al. 28 ; Feng et al. 10 ;
Schwabe et al. 40 ) can reduce, terminate, or block seizure or seizure progression and that transplantation of unstimulated GABA producing cells can reduce seizure severity (Thompson et al. 42 ; Gernert et al. 13 ; Ross et al. 39 ; Thompson and Suchomelova 43 ;
Thompson 44 ; Castillo et al. 5 ). Hybrid cell silicon devices might be able to deliver the required selectivity for inhibition over excitation by chemical rather than direct electrical modulation. While the mode of therapy for direct neural stimulation and hybrid cell silicon stimulation is different, again the relationship between the electrical input stimulus and the neurotransmitter release is critical. In order for hybrid cell silicon implant to work, we must be able to calibrate neurotransmitter release from the target neurons based on electrical stimulation parameters. Here we show that electrode stimulation parameters, current amplitude and frequency, can be used to tune neurotransmitter release from both the P19 and CN1.4 cell lines. The differences in these tuning relationships indicate that a mature neuronal phenotype will be optimal for designing hybrid cell silicon devices using human-derived cell sources. Immunofluorescence staining was used to characterize the P19 and CN1.4 cells. Briefly, cells were fixed in situ using 4% paraformaldehyde for 10 minutes, followed by washing in PBS and permeabilization with 0.1% Triton X-100. Cells were blocked in PBS with 10% or 20% normal goat serum. Antibodies used included GAD6 (U. Iowa Hybridoma Bank), GAD65/67 (AbCam), β-tubulin III (AbCam), neurofilament (AbCam), syntaptotagmin (DSHB), GABA (Sigma) and PSD-95 (BD Transduction Laboratories). Primary antibodies were allowed to incubate overnight at 4 C. Appropriate secondary antibodies were chosen conjugated to AlexaFluor dyes, and allowed to incubate for 1 hour at room temperature. Nuclear staining was done with Hoechst 33258 or Propidium Iodide (PI). After the final washing, the cells were analyzed using a Bio-Rad Radiance Multiphoton confocal microscope.
Experimental Methods

Materials
Electrical Stimulation. Stimulation experiments were conducted 12-14 days post RA-treatment for P19 cells and 10 days after temperature shifting to 39
• C for CN1.4-GAD65 cells. Prior to electrical stimulation, cells were washed once with 37
• C phosphate buffered saline, pH 7.4 (PBS). The PBS was then immediately replaced with 37
• C Locke's buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 1 mM MgCl2, 3.6 mM NaHCO2, 5 mM HEPES, 20 mM Glucose). The cells were kept in a temperaturecontrolled cabinet, set at 37
• C for the duration of the stimulation experiment. Cells were stimulated with a custom linear, adjustable waveform microstimulator. This stimulator was equipped with a pair of silver electrodes.
Electrodes were produced by electroplating 22 gauge silver wire for 45 minutes with KCl at 7-8 Volts. At the frequency range used, these electrodes have an impedance range from 3 kΩ-20 kΩ. The electrodes were held 1 cm apart, using a custom plexiglass holder. The electrodes were placed in the wells after several seconds of system equilibration. Each electrode was at the extreme diameter of each well. The volume of fluid in the well was the same for each sample. With this configuration the electrode field will be the strongest in the path connecting the two electrodes. Other field lines will bow out so that the field looks like a half sphere in the well.
All stimulations were performed using a pulse wave with a 50% duty cycle, and a 50 ns edge rise time. At the frequencies we used in this study the current is best described as a pulsatile or square wave alternating current (ac). For amplitude sweeps, the frequency was maintained at 250 Hz, and the amplitude was varied from 50 µA to 350 µA. Selection of 250 Hz was based on preliminary studies that indicated optimal release at this level. For frequency sweeps, the amplitude of stimulation was maintained at 150 µA, and the frequency was varied in the high frequency range, from 100 Hz to 1000 Hz. The capacitance of Ag/AgCl electrodes at approximately 100 Hz to 1 kHz is 0.2 µF to 2.94 µF, so in this frequency range our electrodes have a charge density of approximately 9.73 −9 µF/mm2 to 143.01 −9 µF/mm 2 . Each stimulation parameter condition was performed on a fresh (i.e. stimulation naïve) cell population to prevent confounding from repeated stimulations. Each stimulation condition was conducted at least in triplicate with a naïve population for each replicate. For cells receiving treatment with nipecotic acid (NA), the inhibitor was added to the cultures in Locke's buffer at a 1 mM concentration 10 minutes prior to stimulation, and stimulation was conducted in the presence of the NA.
In all experiments, cells were stimulated for two minutes and the extracellular fluid was then extracted from the cell culture plate.
Neurotransmitter Measurements. The extracellular fluid was subject to solid-phase extraction to eliminate salts from the Locke's buffer. Extraction cartridges from Waters (Oasis MCXtype) were used as described by the manufacturer. Glutamate was eluted using methanol/formic acid (90/10%) as the mobile phase, and GABA was eluted with methanol/ammonium hydroxide (95/5%). These fractions were mixed and evaporated to dryness for derivatization. The residue from the dried fractions were reconstituted in anhydrous pyridine, and all sugar moieties were blocked with ethylhydroxylamine. Following blocking, the samples were derivatized with N -(tert-butyldimethylsilyl)-N -methyltrifluoroacetamide (MTBSTFA, RegisTech).
Following derivatization, the samples were analyzed by GCxGC/ToF MS (Agilent 6890N/Leco, Pegasus III). The sample was injected, using a split injection into the gas chromatograph (5 µL), using helium as a carrier gas at 1.0 mL/minute. The first dimension was set for a gradient of 10
• C/minute. The retention time and m/z profiles for GABA and glutamate were determined through the consistent use of control samples. The control spectra are shown in supplementary information (Supplementary Fig. 1 ). At the given retention time for the analyte of interest, the m/z profile was examined, and the appearance of at least two positive peaks was considered a positive sample. To quantify, the effective area under the curve was summed across the peaks of interest, followed by normalization and calibration as described.
Each sample set analyzed in this manner was subject to calibration and normalization parameters. The calibration parameter quantified the amount of neurotransmitter present in the samples. This calibration was performed by running spiked control samples with every sample set. The control samples were treated in an identical manner to the experimental samples. These spiked controls represented three mass quantities of GABA and glutamate within the range of expected concentrations. The curve areas were quantified and then a linear calibration established to convert area to a defined mass. Following calibration, the samples were normalized to total cell counts for CN1.4-GAD65 cells or total neuron counts for P19 cells.
Flow Cytometry. The number of neurons in P19 samples was quantified for each experiment. To accomplish this, several wells of cells (at least 3 per experiment) were counted for total cell counts, using trypsin-EDTA and a hemocytometer. The cells were then fixed overnight in a mixture of 30% FBS:PBS (50:50) and 70% ethyl alcohol (70% in PBS). Following fixation, the cells were separated from the fixative using centrifugation, and permeabilized/blocked for 1 hour at room temperature in 0.1% Triton X-100 and 10% FBS in PBS supplemented with 0.1% bovine serum albumin and 0.1% sodium azide. Following blocking, the neuron specific β-tubulin III antibody (Tuj1) was used to label the neuronal cells. This antibody is preconjugated with Alexa488, eliminating the need for any secondary antibody. The cells were gently agitated in the presence of the antibody overnight at 4
• C. The cells were then washed three times in PBS supplemented with 0.1% BSA (to reduce clumping) and 0.1% sodium azide (as a preservative), and resuspended in the same buffer. Flow cytometry was performed on a Beckman Coulter Epics Altra cell sorter with a coherent spectrum laser, with an excitation wavelength of 488 nm. At least 50,000 cells were analyzed for each experiment.
Statistical Methods. Polynomial regression was utilized to evaluate the relationship between the neurotransmitter release and the stimulations, and the final models were selected using stepwise model selection procedure. Such relationships were first investigated separately for each of the two conditions (with and without inhibitor), then we combined them to test whether the inhibitor, nipecotic acid, affected the extracellular neurotransmitter levels when the stimulations shared the same frequency but had different amplitudes. Other within and between group comparisonswereperformed similarly (Table 1) .
Model assumptions, such as normality and constant variance, were checked for each model. Logarithm transformation was employed to satisfy these assumptions, and the explanatory variables were standardized to avoid multicollinearity. No outliers were detected using Cook's distance.
Results and Discussion
P19 cells were selected because they are a wellcharacterized cell line that have stem cell like properties, can differentiate into a network of inhibitory and excitatory neurons that release glutamate and GABA and can form functional synapses. Here immunocytochemical characterization confirms this neuronal state. After retinoic acid treatment, P19 cells express the neuronal marker, β-tubulin III, (Fig. 1a) and express the GABA producing enzyme glutamic acid decarboxylase (Fig. 1b) , indicating a neuronal phenotype capable of GABA production. The P19s were also examined for the presence of structural synapses, using pre-and post-synaptic protein markers (Christopherson et al. 6 ). Synaptotagmin, located on the pre-synaptic membrane is involved in early synaptic docking. PSD-95 is a post-synaptic protein, involved in organization of receptors and signal transduction molecules at the synaptic contact zone (Kornau et al. 21 ; Hunt et al. 16 ;
El-Hussein et al. 9 ). The P19 cells show expression of both of these indicator proteins. Some groups of cells showed co-localization, indicating at least some level of structural synapse formation (Figs. 1c and 1d ). Together these results indicate the RA treated P19 cells differentiate into neurons capable of synaptic release of neurotransmitter. Immunocytochemical characterization also confirmed that the CN1.4-GAD65 cells express GAD65 and produce GABA, as expected (Figs. 2a and 2c) . In addition these cells were found to be positive for neurofilament protein after temperature shifting to 39
• C, indicating a neuronal lineage (Fig. 2b ).
Glutamate and GABA release from mature P19 neurons increases monotonically with stimulation amplitude. Electrical stimulation induces the release of neurotransmitter from neurons. Increasing current amplitude should increase the magnitude of release within a finite range; however, the quantitative nature of this relationship for a bulk neuronal population is not known. To determine this relationship, we delivered a current stimulation to the RA-treated P19 cells at varying amplitudes and measured both the glutamate and GABA released following stimulation. These measurements assume that all of the neurotransmitter release originates from the neurons, as opposed to the astrocytes, oligodendrocytes, and fibroblasts in the cell population. GAD expression and GABA production is typically restricted to neurons in neural populations, so GABA release is expected to derive only from the neurons. Astrocytes can also release glutamate by calcium 
Glutamate and GABA release from immortalized embryonic GAD-expressing cells depends non-linearly on stimulation amplitude.
In contrast to the P19 cells, CN1.4-GAD65 cells showed a strongly non-linear relationship between released neurotransmitter and stimulation amplitude (Fig. 3b) . Peak release occurred at ∼ 250 µA for both neurotransmitters. Despite the induced expression of the GABA producing enzyme, GAD65, these immature neural cells, released equivalent levels of GABA and glutamate. GAD produces GABA by the decarboxylation of glutamate, which is expected to be present in all neural cells as a metabolite. This result indicates that both glutamate and GABA are likely leaving the cells via similar, possibly nonselective mechanisms. The total release for both glutamate and GABA ranged between ∼ 10 pg/cell to ∼ 50 pg/cell and was more than one order of magnitude lower compared to the more mature P19 neurons.The CN1.4-GAD65 cell line had a previously reported basal (i.e. unstimulated) release of ∼ 5fmol/cell (∼ 0.5 pg/cell) (Thompson et al. 42 ).
Based on this, stimulation increases GABA release by 2 to 10 times depending upon the stimulation amplitude.
Blocking GABA uptake by GAT increases extracellular GABA and decreases extracellular glutamate during stimulation of P19 cells. Plasma membrane GABA transporters (GATs) typically serve as the primary uptake mechanism of GABA into astrocytes and neurons after release (Guastella et al. 14 ; Minelli et al. 32 ). GAT is an electrogenic transporter that co-transports sodium and chloride ions with GABA (Kanner 20 ). As a result the electrochemical gradient during depolarization can drive the transporter in the reverse direction, resulting in a net efflux of GABA (Wu et al. 45 ; Sitte et al. 41 ; Richerson and Wu 38 ). To investigate the role of the GATs on the extracellular GABA and glutamate levels, we tested the effect of GAT inhibitor, nipecotic acid (NA). NA and its derivatives, are potent inhibitors of GABA uptake by acting as competitive substrates with GABA for GAT transport (P. Krogsgaard-Larsen
35
). NA inhibits both astrocytic and neuronal uptake in mouse (Liu et al. 26 ).
Application of GAT inhibitors in vivo results in the increase in extracellular GABA levels (Dalby 7 ) .
Figures 4a and 4b shows that like the neuronal networks in vivo, P19 cells demonstrate elevated extracellular GABA and decreased glutamate in the presence of nipecotic acid. This result is consistent with a block of the active uptake of GABA by neuronal and/or astrocytic GAT resulting in a direct increase in extracellular GABA. This increase in inhibition in the network likely leads to the decrease in glutamate activity. In order to mathematically characterize the relationships between stimulation amplitude and neurotransmitter release level and determine the statistical significance of the effects of the GAT inhibitor at different amplitudes, we used linear regression to establish a simplest best fit polynomial function for each relationship. To meet the required assumptions of constant covariance and normality we used a log transformation of the dependent variable, neurotransmitter release level (either glutamate or GABA). The independent variable, stimulation amplitude, was normalized relative to the median amplitude by a linear transformation. Graphs and equations for the resulting transformed data sets and model fits are provided in the supplemental information.
The effect of the inhibitor on both glutamate and GABA levels in the P19 cells was found to be statistically significant (P ≤ 0.0001). The effect occurred over the entire stimulation range; however, for GABA, the model also revealed an interaction between the inhibitor and the stimulation amplitude such that the inhibitor had the highest effect at intermediate stimulation amplitudes. The fitting revealed a statistically significant (P = 0.006) interaction term between the inhibitor and the quadratic amplitude term. No such interaction was revealed for glutamate and NA; the inhibitor seemed to increase the entire calibration curve for glutamate as a function of stimulation with equal effects at all stimulation amplitudes.
Stimulated glutamate or GABA release from GAD expressing embryonic cortical cells is insensitive to nipecotic acid. Nipecotic acid had no effect on CN1.4-GAD65 cells indicating that mature mechanisms for GABA uptake may not yet be developed in the cells (Figs. 4c and 4d) . We found no statistically significant effect on either GABA or glutamate release in these cells. Graphs and equations for the resulting transformed data sets and model fits are provided in the supplemental Fig. S2 .
A lack of effect of NA on the CN1.4 cells is consistent with the known stage of development of these cells. The embryonic cortical mouse cells (CN1.4) were harvested at embryonic day 13 (E13). At this stage, the cells were shown to express some neuronal markers such as neuron-specific enolase (NSE) and neurofilament 200kD (NF200) as well as lack glial markers such as glial fibrillary acid protein(GFAP) and myelin basic protein (BP) (Bongarzone et al. 3 ). Although in mouse weak GAT1 immunoreactivity can be observed as early as E13 in the primordial plexiform,robust GAT1 (neuronal) and GAT4 (astrocytic) protein expression is not detected in the cerebral cortex until late embryonic (E18-E20) and postnatal development (Frantisek 12 ).
It is likely that the CN1.4 cells do not yet express significant levels of active GAT. Regardless, the NAindependence of the stimulated increases in extracellular GABA and glutamate indicate that reversal of the plasma membrane transporter is not the primary path of glutamate and GABA release from the cell.
Glutamate and GABA release in P19 cells is maximized at optimal frequencies. Frequency is a critical parameter in functional neural stimulation.
To determine the effect of frequency stimulation on extracellular GABA and glutamate levels in a mixed network of excitatory and inhibitory neurons, we stimulated the P19 cells at varying frequencies between 100 Hz and 1 kHz. Figure 5A shows that glutamate levels peaked at stimulation level of 250 Hz, while GABA release peaked at 400 Hz. These levels of stimulation are in a high frequency regime and are consistent with the hypothesis that high frequency (> 180 Hz) stimulation is not simply a temporal lesion or temporary inhibition of activity. Figure 5 shows that the P19 neurons require an extraordinarily high frequency stimulation (> 500 Hz) to bring neurotransmitter release levels down to a lower level.
As a measure of consistency between experiments, we compared the glutamate and GABA release levels from both the amplitude sweep (Fig. 3a) and the frequency sweep (Fig. 5a) experiments. Both experiments included stimulation parameters of 150 µA and 250 Hz. For GABA these values were 0.34 ± 0.02 ng/neuron and 0.48 ± 0.16 ng/neuron for the amplitude and frequency sweeps respectively. For glutamate, the levels were 1.45 ± 0.16 and 1.25 ± 0.19 ng/neuron for the amplitude and frequency sweeps respectively. This checkpoint indicates that the quantitative results were consistent and repeatable across the two sets of experiments.
Consistent with the amplitude sweep experiments, the release levels of glutamate compared to GABA were consistently higher at all frequencies. We tested the significance of this effect by combining the data sets and including the neurotransmitter type as well as the frequency as independent variables in the regression model. Neurotransmitter type was found to be statistically significant (P = 0.0003), indicating that the observed difference between the (a) Glutamate and GABA release from P19 neurons have different optimal frequencies. Glutamate was consistently greater than GABA across the entire frequency range (P = 0003). The peak glutamate release at 250 Hz was greater than the minimum release at 850 Hz (P = 0.017). The peak GABA release at 400 Hz was statistically different from the minimum release at 850 Hz (P = 0.09). (b) There is no statistical difference between the dependence of glutamate and GABA release on frequency.Error bars reflect the standard error of the mean.
glutamate and GABA release levels was significant. No interaction between neurotransmitter type and frequency was found indicating that higher glutamate levels were consistent across all frequencies tested.
Glutamate and GABA release in CN1.4-GAD65 cells is weakly dependent upon frequency. In contrast to the P19 neurons, the immature GAD expressing cortical cells had a much less pronounced increase in neurotransmitter levels as frequency was increased above 100 Hz. There was no significant difference between the maximum and minimum release levels for glutamate or GABA measured by an unpaired students t-test. Linear regression of the log transformation of the GABA concentration as a function of normalized frequency resulted in only the intercept as a significant term, indicating a lack of a statistically significant frequency effect on extracellular GABA levels. Similar analysis revealed a weak dependence of glutamate levels on frequency.
Again consistent with the amplitude sweep results for the CN1.4-GAD65 cells there was no significant difference between glutamate or GABA release across all frequencies. This was tested again by fitting a polynomial model by linear regression including both frequency and neurotransmitter types as factors.
As a measure of consistency, we compared the extracellular neurotransmitter levels produced by 150 uA and 250 Hz stimulation observed in the amplitude sweep experiments (Fig. 3b) and the frequency sweep experiment (Fig. 5b) . Like those of the P19 cells, the measured levels for the CN1.4-GAD65 cells were also consistent. GABA levels were measured to be 0.01 ± 0.005 and 0.024 ± 0.008 ng/cell, for the amplitude and frequency sweep experiments, respectively. Glutamate levels were measured to be 0.013 ± 0.004 and 0.019 ± 0.008 ng/cell.
Conclusions
Stimulation of both cell types in the high frequency range induced increased levels of extracellular glutamate and GABA. This result is consistent with the hypothesis that the mechanism of HFS is not simply a temporary block of activity by overstimulation, but rather activation of both inhibitory and excitatory cells. If stimulation parameters such as frequency have different tuning curves for excitation or inhibition, one may be able to tune the stimulation to be more selective for one versus another. Indeed the P19 cells had different peak frequencies for increasing extracellular GABA and glutamate levels, but the peaks were broad and had significant overlap. These in vitro results provide insight, but need to be followed up with in vivo studies. The 3D architecture of cells, vasculature, and extracellular matrix is clearly different compared to these cell culture systems. The spatial distribution of extracellular neurotransmitter levels would be altered from the in vitro situation due to different sources and sinks of neurotransmitter around the device as well as altered diffusion through the extracellular space.
Interpreting these results for the design of direct neural stimulation is somewhat limited due to the use of cell lines; however, in the case of hybrid cell silicon implants the stimulation target is by definition exogenous cells that must be cultured outside of the body prior to implantation.The results presented here are directly relevant to this therapeutic approach. Most likely the cell source for a human therapy will be stem cell derived. A key insight from this work is that mature neurons will likely be required to achieve a linear calibration between stimulation amplitude and release level.In addition, even at the highest stimulation amplitudes, the engineered GABAergic cells released much less GABA on a per cell basis compared the mature neurons despite being engineered to express GAD. Stem cells may need to be pre-differentiated prior to transplantation or implanted in an environment that supports differentiation into neurons of a GABAergic phenotype. Regardless, this work demonstrates that neurotransmitter release can in fact be calibrated by electrical stimulation providing in vitro proof-of-concept for the hybrid cell silicon approach.
